Pa. Superior Court Won't Rehear Reglan Preemption Appeal

Law360, Philadelphia (October 7, 2013, 3:30 PM EDT) -- Pharmaceutical companies looking to dodge thousands of state law claims for alleged injuries related to generic versions of the digestive drug Reglan were dealt a loss Wednesday after the Pennsylvania Superior Court refused to rehear an appeal over whether the suits were preempted by federal law.

The court rejected a bid by Teva Pharmaceutical USA Inc. seeking an en banc rehearing of a July decision finding that thousands of Reglan-related product liability suits pending in the Philadelphia County Court of Common Pleas could survive preemption under...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.